

CORRESPONDENCE

Open Access



Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value

Anna Citarella^{1†}, Zein Mersini Besharat^{1†}, Sofia Trocchianesi¹, Tanja Milena Autilio¹, Antonella Verrienti², Giuseppina Catanzaro¹, Elena Splendiani³, Zaira Spinello¹, Silvia Cantara⁴, Patrizia Zavattari⁵, Eleonora Loi⁵, Cristina Romei⁶, Raffaele Ciampi⁶, Luciano Pezzullo⁷, Maria Grazia Castagna⁴, Antonio Angeloni¹, Rosella Elisei⁶, Cosimo Durante², Agnese Po^{8*†} and Elisabetta Ferretti^{1†}

Abstract

Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine tumour whose diagnosis includes evaluating calcitonin serum levels, which can present fluctuations unrelated to MTC. Here, we investigated circulating DNA fragmentation and methylation changes as potential biomarkers using ddPCR on cell-free DNA (cfDNA) isolated from the plasma of MTC patients. For cfDNA fragmentation analysis, we investigated the fragment size distribution of a gene family and calculated short fragment fraction (SFF). Methylation analyses evaluated the methylation levels of CG_16698623, a CG dinucleotide in the MGMT gene that we found hypermethylated in MTC tissues by analyzing public databases. The SFF ratio and methylation of CG_16698623 were significantly increased in plasma from MTC patients at diagnosis, and patients with clinical remission or stable disease at follow-up showed no significant SFF difference compared with healthy subjects. Our data support the diagnostic value of cfDNA traits that could enable better management of MTC patients.

Keywords Medullary thyroid carcinoma, Rare tumour, Cell-free DNA, Circulating DNA methylation, Circulating DNA fragmentation, Circulating biomarker

[†]Anna Citarella and Zein Mersini Besharat are co-first authors.

[†]Agnese Po and Elisabetta Ferretti are co-last authors.

*Correspondence:

Agnese Po

Agnese.Po@uniroma1.it

¹Department of Experimental Medicine, Sapienza University of Rome, Rome 00161, Italy

²Department of Translational and Precision Medicine, Sapienza University of Rome, Rome 00161, Italy

³Department of Movement, Human and Health Sciences, University of Foro Italicco, 00135 Rome, Italy

⁴Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena 53100, Italy

⁵Department of Biomedical Sciences, Unit of Biology and Genetics, University of Cagliari, Cagliari 09042, Italy

⁶Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa 56126, Italy

⁷Thyroid Surgical Unit, IRCCS Fondazione G.Pascale, Naples 80131, Italy

⁸Department of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

To the editor

Medullary thyroid carcinoma (MTC) is a rare tumor arising from parafollicular C-cells [1]. Patients with intrathyroidal tumour have an excellent 10-year survival, which worsens in patients with nodal or distant metastasis at diagnosis [1].

MTC diagnosis includes fine-needle aspiration biopsy (FNAB) in thyroid nodules and deregulated serum and/or FNAB calcitonin (Ct) levels. However, the use of serum Ct presents limitations, such as FNAB being invasive and identifying half of the MTCs [2], rare Ct-negative MTCs [3], and altered levels in non MTC-related conditions like C-cell hyperplasia and other neuroendocrine tumors [4, 5]. Therefore, the identification of additional non-invasive biomarkers is a major challenge for diagnosis and disease monitoring.

Plasma cell-free DNA (cfDNA) is released in the bloodstream by cells and is a promising source for diagnostic and prognostic biomarkers, such as tumor-specific mutations and epigenetic features [5]. Indeed, in MTC patients, cfDNA was previously analyzed to evaluate tumor-specific mutations for minimal residual disease and response to treatment monitoring [6, 7]. Epigenetic features of cfDNA, such as fragmentation and methylation patterns, have been investigated: a high proportion of short cfDNA fragments was reported in cancer patients [8], and circulating methylation signatures were recently exploited for multicancer detection [9]. Of note, cfDNA epigenetic features have never been investigated in MTC.

We therefore evaluated plasma cfDNA fragmentation and methylation using droplet digital PCR (ddPCR) in MTC patients enrolled in the study. Patients' features and detailed methods can be found in the supplemental material.

In fragmentation analysis, we focused on the prevalence of the short fragment fraction (SFF) using an assay that targets three fragment sizes from the conserved Olfactory Receptor (OR) gene family, as previously described [10]. We analyzed pre-surgical samples from 8 MTC patients (Supplementary Table 1) versus 6 controls (Supplementary Table 2) and found that the SFF ratio significantly increased in MTC (Fig. 1A), showing higher levels in patients with extra-thyroid extension (Supplementary Fig. 1A).

Moreover, ROC curve analysis resulted in an area under the curve (AUC) of 0.87 ($p=0.02$), showing that the SFF discriminates MTC patients from controls (Fig. 1B). No correlation between the SFF and Ct levels was observed (Supplementary Fig. 1B). SFF in 3 disease-free patients three months after surgery showed no significant decrease compared to pre-surgery SFF levels (Fig. 1C). Notably, the SFF evaluated in a second cohort of 10 post-surgery MTC patients with stable (i.e. structural or

biochemical) disease or remission showed no differences compared to healthy donors (Fig. 1D), suggesting that elevated SFF is a feature of patients with active MTC.

To investigate cfDNA methylation, we first searched for alterations by interrogating publicly available methylation data from MTC and normal thyroid (detailed in the supplemental material). Among the top 10 significantly methylated CG dinucleotides in MTC compared to normal thyroid (Supplementary Table 3), we focused on two dinucleotides CG_16698623 and CG_17686260 both located in the MGMT gene since MGMT is hypermethylated in other types of tumors [11]. DdPCR was performed for CG_16698623 (MGMT_623CG) methylation because the flanking sequence of CG_17686260 contained CG dinucleotides with unknown methylation status.

We performed the methylation analysis in the pre-surgical plasma of 9 MTC patients compared to controls. MGMT_623CG was hypermethylated in MTC patients (Fig. 2A), with higher levels in patients with extra-thyroid extension (Supplementary Fig. 2A).

The ROC curve analysis with an AUC equal to 0.89 ($p=0.0087$) confirmed its performance (Fig. 2B). No significant correlation between MGMT_623CG methylation and Ct levels was observed (Supplementary Fig. 2B). However, two patients with low Ct had high MGMT_623CG methylation, suggesting that MGMT_623CG methylation could identify MTC patients without diagnostic Ct levels.

We evaluated MGMT_623CG methylation in 4 disease-free MTC patients three months after surgical resection, and we observed a negative trend compared to pre-surgery levels (Fig. 2C).

Interestingly, the positive trend in SFF and methylation of MGMT_623CG with advanced tumor stages suggest that these assays could be further investigated for their putative prognostic value. Univariate analyses showed no association of cfDNA features with clinical data such as age and sex (data not shown). The lack of statistical significance for the correlation with staging and early follow-up is presumably due to the small number of samples analyzed, which is the main limitation of our work.

Our data, obtained using a reproducible technology like ddPCR, support the diagnostic value of cfDNA features, which could be clinically valuable as additional non-invasive biomarkers in MTC patients. Validation of our results in independent cohorts could support the clinical application that may facilitate early MTC diagnosis and monitoring. Further studies will likely clarify whether cfDNA features could also guide the extension of surgery in MTC patients.




Fig. 1 Evaluation of cfDNA fragmentation. **(A)** SFF was calculated as the proportion of short fragments as detailed in supplementary methods in MTC patients and healthy donors (controls, HD) plasma samples. Unpaired t-test * $p < 0.05$ **(B)** ROC curve of SFF in a cohort of 8 MTC and 6 healthy donors subjects (Area under the curve AUC=0.8750; p-value=0.0201). Black line=sensitivity, red line=identity. **(C)** SFF in MTC patient before (T0) and three months after the surgical resection (T1). **(D)** SFF in post-surgery 11 MTC patients and 15 healthy donors (HD) plasma samples. SD (Structural disease); BD (Biochemical disease); DF (Disease Free) compared to HD (Healthy Honors; mean value in black line) SFF.




Fig. 2 Evaluation of MGMT_623CG methylation. **(A)** MGMT_623CG methylation percentage in MTC patients and healthy donors (HD) plasma samples. The methylation rate was calculated by using the bisulfite converted Human Methylated DNA and human unmethylated DNA as positive and negative controls, respectively. Unpaired t-test * $p < 0.05$. **(B)** ROC curve of MGMT_623CG methylation percentage in a cohort of 9 MTC patients and 7 healthy donors subjects (AUC = 0.8750; p -value = 0.0201). Black line = sensitivity, red line = identity. **(C)** MGMT_623CG methylation percentage in MTC patients before (T0) and three months after the surgical resection (T1)

List of abbreviations

MTC	Medullary thyroid carcinoma
Ct	Calcitonin
cfDNA	Cell-free DNA
ddPCR	Droplet Digital PCR
SFF	Short fragment fraction
AUC	area under the curve

Author contributions

AC, AP and EF conceived the study; AP coordinated the scientific team; EF allocated the funding; AC, AP, ZMB and TMA analyzed data; AC, ST, TMA, GC, ES, ZS generated experimental data; CD, SC, CR, RC, FD, LP, MGC, RE provided patients' samples and clinical data; AC, EL, PZ designed primers and probe for methylation analysis; AC, TMA, AP wrote the manuscript; ZMB, AV, AA and EF reviewed the manuscript. All authors contributed with suggestions after a critical reading of the draft and approve its submission for publication.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40364-023-00522-4>.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

T.M.A. is fellow of Network Oncology and Precision Medicine, Dpt. Experimental Medicine, Sapienza University of Rome.

Funding

This work was supported by co-funding of the European Union - Next Generation EU, Mission 4 Component 2 Investment 1.5, project Rome Technopole - code ECS 00000024 (CUP: B83C22002820006) (Prof. Elisabetta Ferretti).

Data Availability

All relevant data are included in the manuscript. Methylation data for MTC tissues are available at GSE72729 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1869223>); methylation data for normal thyroid are available at TCGA data <https://portal.gdc.cancer.gov/>.

Declarations

Ethics approval and consent to participate

All subjects included provided informed consent for sample collection and after approval of the ethical committee (Protocol: OTC-CBSS-1114, Ethical committee reference: 4940).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 2 June 2023 / Accepted: 5 September 2023

Published online: 19 September 2023

References

1. Kim M, Kim BH. Current Guidelines for Management of Medullary Thyroid Carcinoma. *Endocrinol Metab* [Internet]. 2021 Jun 1 [cited 2023 Mar 30];36(3):514–24. Available from: <http://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2021.1082>.
2. Essig GF, Porter K, Schneider D, Debora A, Lindsey SC, Busonero G et al. Fine Needle Aspiration and Medullary Thyroid Carcinoma: The Risk of Inadequate Preoperative Evaluation and Initial Surgery when Relying upon Fna Cytology Alone. *Endocr Pract* [Internet]. 2013 Nov 1 [cited 2023 Mar 30];19(6):920–7. Available from: <http://www.endocrinepractice.org/article/S1530891X20431301/fulltext>.
3. Kim SJ, Yun HJ, Shin SJ, Lee YS, Chang HS. Serum calcitonin-negative medullary thyroid carcinoma: a Case Series of 19 patients in a single Center. *Front Endocrinol (Lausanne)*. 2021;12.
4. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab* 2009 51 [Internet]. 2009 Jan [cited 2023 Mar 30];5(1):35–44. Available from: <https://www.nature.com/articles/ncpendmet1023>.
5. Leimbach RD, Hoang TD, Shakir MKM. Diagnostic Challenges of Medullary Thyroid Carcinoma. *Oncology* [Internet]. 2021 Jun 1 [cited 2023 Mar 30];99(7):422–32. Available from: <https://www.karger.com/Article/FullText/515373>.
6. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T et al. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. *J Clin Endocrinol Metab* [Internet]. 2017 Sep 1 [cited 2023 Mar 30];102(9):3591–9. Available from: <https://academic.oup.com/jcem/article/102/9/3591/3979821>.
7. Ciampi R, Romei C, Ramone T, Matrone A, Prete A, Gambale C et al. Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma. *J Clin Endocrinol Metab* [Internet]. 2022 Jul 14 [cited 2023 Mar 30];107(8):e3420–7. Available from: <https://academic.oup.com/jcem/article/107/8/e3420/6574259>.
8. Gao Q, Zeng Q, Wang Z, Li C, Xu Y, Cui P et al. Circulating cell-free DNA for cancer early detection. *Innov* [Internet]. 2022 Jul 12 [cited 2023 Mar 30];3(4). Available from: <http://www.cell.com/article/S2666675822000558/fulltext>.
9. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol* [Internet]. 2020 Jun 1 [cited 2023 Mar 30];31(6):745–59. Available from: <http://www.annalsofncology.org/article/S0923753420360580/fulltext>.
10. Alcaide M, Cheung M, Hillman J, Rassekh SR, Deyell RJ, Batist G et al. Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. *Sci Reports* 2020 101 [Internet]. 2020 Jul 28 [cited 2023 Mar 30];10(1):1–10. Available from: <https://www.nature.com/articles/s41598-020-69432-x>.
11. Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT Status as a clinical biomarker in Glioblastoma. *Trends in Cancer*. 2020;6(5):380–91.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.